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Both cannabis use and the dopamine receptor (DRD2) gene 
have been associated with schizophrenia, psychosis-like 
experiences, and cognition. However, there are no published 
data investigating whether genetically determined varia-
tion in DRD2 dopaminergic signaling might play a role in 
individual susceptibility to cannabis-associated psychosis. 
We genotyped (1) a case-control study of 272 patients with 
their first episode of psychosis and 234 controls, and also 
from (2) a sample of 252 healthy subjects, for functional 
variation in DRD2, rs1076560. Data on history of cannabis 
use were collected on all the studied subjects by administer-
ing the Cannabis Experience Questionnaire. In the healthy 
subjects’ sample, we also collected data on schizotypy and 
cognitive performance using the Schizotypal Personality 
Questionnaire and the N-back working memory task. In 
the case-control study, we found a significant interaction 
between the rs1076560 DRD2 genotype and cannabis use 
in influencing the likelihood of a psychotic disorder. Among 
cannabis users, carriers of the DRD2, rs1076560, T allele 
showed a 3-fold increased probability to suffer a psychotic 
disorder compared with GG carriers (OR  =  3.07; 95% 
confidence interval [CI]: 1.22–7.63). Among daily users, T 
carrying subjects showed a 5-fold increase in the odds of 
psychosis compared to GG carriers (OR = 4.82; 95% CI: 
1.39–16.71). Among the healthy subjects, T carrying can-
nabis users had increased schizotypy compared with T car-
rying cannabis-naïve subjects, GG cannabis users, and GG 
cannabis-naïve subjects (all P ≤ .025). T carrying cannabis 
users had reduced working memory accuracy compared 
with the other groups (all P ≤ .008). Thus, variation of the 
DRD2, rs1076560, genotype may modulate the psychosis-
inducing effect of cannabis use.
Key words: dopamine receptors type 2/G × E interaction/
schizophrenia/schizotypy/working memory.
Introduction
Schizophrenia is a complex disorder in which both 
genetic variation and environmental factors play an eti-
ological role.1–4 Findings from epidemiological studies 
suggest that cannabis use represents an environmental 
risk factor for schizophrenia and psychotic disorders.5,6 
Meta-analyses indicate that psychosis risk rises with 
increasingly heavy cannabis exposure, and estimate that 
cannabis use may account for 8–14% of schizophrenia 
cases.7,8 Recent evidence from studies on healthy subjects 
suggests that cannabis use is associated with increased 
levels of schizotypy9 and can induce transient psychotic 
symptoms.10 However, the effect of cannabis use on cog-
nition remains unclear.11 Inconsistent findings have been 
reported with cannabis use being associated with poor 
cognition in healthy subjects,12–15 but with better cogni-
tion among psychotic patients.16–20
The neurobiological mechanisms underlying how 
cannabis exposure may confer increased schizophrenia 
susceptibility are poorly understood.21–24 Increased dopa-
mine synthesis capacity and release have been reported in 
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psychotic patients as well as in the prodromal phase of 
psychosis.25,26 Drugs that increase dopamine release can 
induce or worsen psychosis27 and the effects of the main 
psychoactive ingredient of cannabis, delta-9-tetrahydro-
cannabinol (Δ9-THC),28 have also been related to dopa-
mine dysfunction.29–31
Experimental data indicate that the dopamine receptor 
type 2 (D2) and schizophrenia are related.32–37 Two iso-
forms of the D2 receptor are known. The D2 long isoform 
(D2L) is mainly postsynaptic and is a target for haloperi-
dol, and the D2 short (D2S) isoform is mainly presyn-
aptic and serves as an autoreceptor regulating dopamine 
synthesis and release.38 These 2 isoforms are coded by D2 
receptor gene (DRD2-11q23) with a mechanism of alter-
native splicing acting at exon 6. A previous study39 char-
acterized a functional single-nucleotide polymorphism 
(SNP) within DRD2 at intron 6 (rs1076560—guanine > 
timine—G > T) associated with relative expression of the 
2 isoforms in the frontal cortex. In particular, the T allele 
shifts splicing from D2S to D2L, decreasing the D2S/
D2L ratio relative to the G allele and causing reduced 
prefrontal presynaptic D2 expression. The T allele has 
also been associated with putative greater levels of stria-
tal dopamine.40
The DRD2 gene has been identified in a number of 
studies including a recent huge genome-wide associa-
tion study35 as a risk gene for schizophrenia. However, 
to our knowledge, no research has been carried out to 
investigate the role of the DRD2 gene in the context of 
the association between cannabis use and psychosis and/
or psychosis-related phenotypes. The aim of this study 
was 2-fold: first, to test if  the functional genetic varia-
tion within DRD2 rs1076560 interacts with cannabis use 
to predict risk of psychosis in a case-control study; sec-
ond, to test if  such variation interacts with cannabis use 
to predict psychosis-related clinical and cognitive pheno-
types in a study of healthy subjects. Given the relevance 
of DRD2 rs1076560 for dopaminergic signaling and psy-
chosis-related phenotypes, including clinical symptoms 
and cognitive alteration, in both schizophrenia patients 
and controls,37–42 we hypothesized that rs1076560 T allele 
would interact with cannabis use to predict increased risk 
of psychosis in the case-control study as well as increased 
schizotypy and reduced cognitive performance in healthy 
subjects.
Methods
Case-Control Study
Participants. Participants were recruited as part of  the 
Genetic and Psychosis project (GAP),43 a case-control 
study, carried out at the Institute of  Psychiatry, London. 
All patients presenting to the Adult services (18–65years) 
of  the South London and Maudsley Mental Health 
NHS Foundation Trust, between December 2005 and 
October 2010, with their first episode of  psychosis, were 
recruited into the study. Patient diagnosis of  nonor-
ganic psychosis (ICD 10: F20-F29 and F30-F33) was 
validated by administering the Schedules for Clinical 
Assessment in Neuropsychiatry (SCAN).44 Cases who 
met criteria for organic psychosis (F09) were excluded. 
About 23% of  the patients approached refused to take 
part in the study; they were more likely to be of  Black 
[χ2(3)=52.9; P < .01] and of  male gender [χ2(1) = 75.3; 
P < .01] compared to those who consented. Therefore, 
ethnicity and gender were controlled for in all the anal-
yses. Over the same time frame, from the area served 
by the mental health units, we recruited a sample of 
control subjects, aged 18–65  years, representing the 
local population in terms of  ethnicity and other main 
sociodemographics according to the appropriate census 
data (www.statistics.gov.uk/census). Those willing to 
take part in the study were administered the Psychosis 
Screening Questionnaire (PSQ)45 and were excluded 
if  they met criteria for a psychotic disorder or if  they 
reported a previous diagnosis of  psychotic illness. For 
a more detailed description of  the GAP study methods, 
see Di Forti et al.46,47
The data presented here are based on the subset of 
the whole GAP sample (N cases  =  272/461, 59%; N 
controls  =  234/389, 60%) recruited up to 2008, when 
the DRD2 genotyping was carried out. On all subjects 
included in our analyses, we have complete data on 
sociodemographics, cannabis, and other drug use.
General Assessment. Sociodemographic data (age, gen-
der, and self-reported ethnicity) on patients and con-
trol subjects were collected using the Medical Research 
Council Social Scale (MRCSS).48
Validation of Self-Report of Ethnicity. To confirm 
self-report of  ethnicity (MRCSS),48 genetic ances-
try was derived using a panel of  57 ancestry informa-
tive genetic markers, as done previously.46 These were 
genotyped using iPLEX technology developed for the 
MassArray platform (Sequenom Inc.). Ancestry scores 
were derived using the program Structure to implement 
a model-based (Markov Chain Monte Carlo) clustering 
algorithm. Having determined the best solution for K 
(the probable true number of  underlying genetic groups) 
in initial analyses, individuals who scored between 96% 
and 100% for genetic cluster membership were used to 
create a 3-way ancestral axis based on Black African 
(n  =  81), European Caucasian (n  =  118), and Asian 
(n = 16) ancestry. These reference groups were used to 
index genetic ancestry for the remaining sample. Further 
information on the makeup of  the marker panel as well 
as a figure reporting plots of  3-way ancestral axis based 
on Black African, European Caucasian and Other are 
available on request. Ninety percent (N = 453) of  par-
ticipants had information on both self-reported ethnic-
ity and ancestry markers. The level of  overall agreement 
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between self-reported and genetic ethnicities (95%) was 
reassuringly high.
History of Cannabis and Other Drugs Use. Participants 
were administered the the Cannabis Experience 
Questionnaire modified version (CEQmdv)43,46 to assess 
their lifetime use of cannabis, stimulants and other drugs 
use. They were also screened for nicotine dependence 
(Fagerström Test for Nicotine Dependence (FTND)49 
and harmful drinking (HD) behavior.
Genotyping. DNA was obtained from all participants 
recruited up to 2008 (N = 512). Seventy-five percent of 
DNA samples used originated from blood and 25% from 
cheek swabs. DNA extraction was performed using stan-
dard phenol-chloroform methods. Off the shelf  Taqman 
assays for DRD2 rs1076560 are available as a kit, at http://
www.appliedbiosystems.com.
Genotype calls, successful call rate 99% (N  =  506), 
were discriminated based on algorithmic membership of 
3 clusters representing homozygote G/G, heterozygote 
G/T, and homozygote T/T genotype classes. A compari-
son of genotype results for individuals with overlapping 
blood and cheek swab DNA revealed there was 100% 
concordance between blood- and cheek-derived genotype 
data.
Ethics. The study was granted ethical approval by the 
South London and Maudsley and Institute of Psychiatry 
Local Research Ethics Committee. All cases and control 
subjects included gave informed written consent, signing 
the consent document, to the publication of data origi-
nating from the study. 
Data Analysis. For the statistical analyses, given the low 
number of subjects carrying 2 copies of the minor allele 
(TT subjects), we collapsed them with the GT subjects 
in group 1 = TT + GT (T carriers) to be compared to 
group 2 = GG carriers. This procedure is consistent with 
a series of earlier studies evaluating polymorphisms with 
low minor allele frequencies, especially when codomi-
nance of the alleles is not known.50 Additional sociode-
mographic and lifestyle variables (gender, age, ethnicity, 
nicotine dependence, harmful alcohol use, and other 
substance use) were modeled as potential confounders. 
Analysis of variance (ANOVAs) and χ2were used to eval-
uate the relation between genotype and demographics 
data as well as the relationship between lifetime canna-
bis use (yes/no) and demographics data, in both patients 
and control subjects. χ2 was used to evaluate the relation-
ship between potential confounders and genotype/can-
nabis use as well as between potential confounders and 
presence of psychotic disorder. Further, χ2 were used 
to determine whether cannabis use was associated with 
DRD2 genotype in both patients and control subjects. 
Finally, a multivariable logistic regression, with history 
of lifetime cannabis use (yes/no) and DRD2 rs10764560 
genotype (GG, T carrier) as independent variables, was 
used to evaluate the main effects as well as the interac-
tion between cannabis use and rs1076560 on presence 
of a psychotic disorder after adjusting for the modeled 
potential confounders. The interaction model examined 
the probability of having a psychotic disorder among 
DRD2 rs1076560 T carrying cannabis users compared 
with GG subjects. Odds ratios (OR) of psychosis among 
T carrying cannabis-naïve subjects were also calculated 
from the estimates provided by the model. Also a mul-
tivariable logistic regression was performed, excluding 
from the analysis control subjects aged 30 (median) or 
less, in order to investigate the possible confounding 
effect of having included in the sample control subjects 
who had not passed the cases’ average age of psychosis 
onset (28.67 ± 8.71 years). Further multivariable logistic 
regressions were performed for each ethnic group (White 
Caucasian, Black Caribbean, Black African, and Asian/
other). A  second multivariable logistic regression with 
lifetime frequency of cannabis use (daily/weekly or less) 
and DRD2 rs10764560 genotype (GG, T carrier) as inde-
pendent variables, was used to evaluate the main effects 
as well as the interaction between frequency of cannabis 
use and rs1076560 on presence of a psychotic disorder, 
after adjusting for the modeled potential confounders. 
The statistical threshold was set at P < .05.
Healthy Subjects Study
Participants. From a sample of 252 healthy subjects, 2 
partially overlapped groups of respectively 170 (sample 
for schizotypal traits evaluation, SCZt) and 221 (sample 
for working memory performance evaluation, WMp) indi-
viduals entered the healthy subjects study. All participants 
were unrelated Caucasians from the region of Puglia in 
Italy. Protocols and procedures were approved by the 
local Institutional Review Board. After complete descrip-
tion of the study to the subjects, written informed consent 
was obtained. Subjects underwent the Structured Clinical 
Interview for DSM-IV to exclude any Axis I psychiatric 
disorder. Exclusion criteria were active cannabis use in the 
past 6 months, use of other stimulant drugs, head trauma 
with loss of consciousness, and any significant medical ill-
ness. Parental socioeconomic status (Hollingshead Scale), 
handedness (Edinburgh Inventory), and total intelligence 
quotient (IQ) (WAIS-R) were also measured.
Genotyping. All subjects were genotyped for DRD2 
rs1076560. This SNP was analyzed with allele-spe-
cific polymerase chain reaction primers as described 
previously.37,39
Substance Use Evaluation. All participants were asked 
about their use of tobacco, alcohol, and cannabis. Users 
were interviewed using the Fagerström Test for Nicotine 
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Dependence (FTND),49 the Tolerance, Worried, Eye-
opener, Amnesia, and Cut down (TWEAK) alcohol screen-
ing test,51 and the CEQ,43 to determine lifetime nicotine 
dependence, HD behavior, and cannabis use, respectively.
Schizotypal Traits Evaluation. Schizotypal traits were 
assessed using the Schizotypal Personality Questionnaire 
(SPQ).52 The SPQ is a self-report scale based on the DSM-
III-R criteria for schizotypal personality disorder and it is 
widely used to screen for schizotypal traits in the general 
population. The SPQ has excellent internal consistency 
(0.91), good test-retest reliability (0.82), discriminant 
validity, and correlates highly with clinical schizotypy.52
Cognitive Performance Evaluation. Subjects completed 
the N-back working memory task.40 Briefly, n back refers 
to how far back in the sequence of stimuli the subject has 
to recall. The stimuli consisted of numbers (1–4) shown 
in random sequence and displayed at the points of a dia-
mond-shaped box. There was a visually paced motor task 
that also served as a nonmemory-guided control condi-
tion (0-back) that simply required subjects to identify the 
stimulus currently seen. In the working memory condi-
tion, the task required recollection of a stimulus seen 2 
stimuli previously (2-back) while continuing to encode 
additionally incoming stimuli.
Data Analysis. As in the case-control study, we col-
lapsed the subjects according to their genotype into group 
1 = TT + GT and group 2 = GG. Gender, age, HD behav-
ior, and nicotine dependence were modeled as potential 
confounders. ANOVAs and χ2were used to evaluate the 
relation between genotype and demographics data as 
well as the relationship between cannabis use (yes/no) 
and demographics data. χ2 was used to evaluate the rela-
tionship between potential confounders and genotype/
cannabis use. Finally, factorial ANOVAs, with cannabis 
use (yes/no) and DRD2 rs1076560 genotype (GG, T car-
rier) as independent variables were used to evaluate the 
main effects as well as the interaction between cannabis 
use and rs1076560 on schizotypy and working memory 
performance. Furthermore, factorial analysis of covari-
ance (ANCOVAs), with cannabis use (yes/no) and DRD2 
rs1076560 genotype (GG, T carrier) as independent vari-
ables, and the potential confounders as covariates, were 
used to evaluate the main effects as well as the interaction 
between cannabis use and rs1076560 on schizotypy and 
working memory performance respectively. Fisher’s test 
was used for post hoc analyses. The statistical threshold 
was set at P < .05.
Results
Case-Control Study
Demographic Measures and Allelic Distribution of the 
DRD2 rs1076560 Genotype. First-episode psychosis 
(FEP) patients and control subjects differed significantly 
for some demographic characteristics. FEP patients 
tended to be significantly younger (F = 3.71, P =  .055) 
and were also more likely to belong to the Black African/
Caribbean ethnic group (χ2  =  41.53, P < .001); the 2 
groups did not differ for gender (P > .1; table 1). On aver-
age, FEP patients’ psychosis onset occurred before age 
30 years (table 1). Table 1 describes the allelic distribu-
tion of the rs1076560 genotype in the 272 FEP and in the 
234 control subjects. After genotype determination, the 
groups (GG, T carriers) displayed Hardy-Weinberg equi-
librium (P > .1). DRD2 genotype was not associated with 
any demographic measure or with diagnosis status (all 
P > .1). Among FEP patients DRD2 genotype was not 
associated with age of psychosis onset (P > .1; table 1).
Pattern of Substance Use. More than two-thirds of 
the FEP patients (70.2%) reported nicotine dependence 
compared with 47.4% of the control subjects (χ2 = 27.14, 
P < .001). Similarly, FEP patients reported more fre-
quently other illicit drug use (41.5%) compared to con-
trol subjects (32.5%; χ2  =  4.42, P  =  .036) but control 
subjects reported more frequently HD behavior (87.2%) 
compared to FEP patients (72.1%; χ2=17.37, P < .001). 
67.6% of the FEP patients and 60.7% of the control sub-
jects reported ever having used cannabis. Among those 
who had a history of  lifetime cannabis use, FEP patients 
were more likely than control subjects to report daily use 
(63.6% vs 39.8%; χ2 = 14.30, P < .001). FEP patients and 
control subjects did not differ in their age of  first use of 
cannabis (P > .1; table 1). On average, psychosis onset 
among FEP patients occurred 12.19 ± 9.38  years after 
the first use of  cannabis (table 1). No patient involved in 
this study started to use cannabis for the first time after 
the psychosis onset.
Case-Control G × E Analyses. The 2 genotype groups 
(TT+GT vs GG) did not differ in their pattern of sub-
stance use (prevalence, frequency or age of first use of 
cannabis) in both FEP patients and control subjects (all 
P > .1; table 1). A multivariable logistic regression adjust-
ing for gender, age, ethnicity, tobacco use (nicotine depen-
dence), stimulants use, and alcohol use (HD behavior) 
showed a significant interaction between lifetime cannabis 
use and DRD2 rs1076560 on probability of suffering from 
a psychotic disorder (N = 506, likelihood ratio test =5.75; 
P = .017). Among subjects having a lifetime history of can-
nabis use, T carrying subjects showed a 3-` increased odds 
of having psychotic disorder (OR = 3.07; 95% confidence 
interval [CI]: 1.22,7.63) when compared with GG subjects. 
On the contrary, among those who had never used canna-
bis, the presence of the T allele was associated with lower 
odds of suffering a psychotic disorder (OR = 0.33; 95% 
CI: 0.13,0.82) compared with GG genotype (figure  1a). 
A  further multivariable logistic regression on psychosis 
risk, adjusting for the modeled potential confounders and 
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excluding from the analysis the younger half of the control 
subjects’ sample (age < 30), indicated that the presence in 
the main analysis of control subjects who have not passed 
the cases’ average age of psychosis onset is not likely to 
affect the results significantly. Further multivariable logis-
tic regressions on psychosis risk performed separately for 
each ethnic group adjusting for the modeled potential con-
founders indicated that ethnicity did not affect the results 
significantly. A  second multivariable logistic regression 
adjusting for the modeled potential confounders showed 
a significant interaction between lifetime frequency of 
cannabis use and DRD2 rs1076560 on risk of psychosis. 
Table 1. Demographic Measures of First-Episode Psychosis Patients and Control Subjects 
FEP Patients  
n = 272 (181 Males)
Control Subjects  
n = 234 (141 Males)
Statistical  
Comparisons
ANOVA
Age (M ± SD) 29.64 ± 8.72 31.23 ± 9.84 F = 3.71, P = .055
Range 18–55 18–61
Distribution n (%) n (%) X2
 18–29 126 (46.3) 101 (43.2) P > .1
 30–39 109 (40.1) 75 (32)
 40–49 31 (11.4) 46 (19.7)
 50–59 6 (2.2) 11 (4.7)
 60–65 — 1 (0.4)
ANOVA
Age of psychosis onset (M ± SD) 28.67 ± 8.71
 GG (M ± SD) 28.51 ± 8.92 P > .1
 T car (M ± SD) 27.62 ± 9.1
n (%) n (%) X2
Self-reported ethnicity χ2 = 41.53, P < .001
 White Caucasian 86 (31.6) 136 (58.1)
 Black Caribbean 81 (29.8) 38 (16.2)
 Black African 75 (27.6) 32 (13.7)
 Asian/other 30 (11) 28 (12)
DRD2 rs1076560 allelic frequency P > .1
 GG 205 (75.4) 174 (74.4)
 GT 62 (22.8) 55 (23.5)
 TT 5 (1.8) 5 (2.1)
Tobacco use χ2 = 27.14, P < .001
 Nicotine dependence 191 (70.2) 111 (47.4)
 Not nicotine dependence 81 (29.8) 123 (52.6)
Stimulants use χ2 = 4.42, P = .036
 Yes 113 (41.5) 76 (32.5)
 Never 159 (58.5) 158 (67.5)
Alcohol use χ2 = 17.37, P < .001
 Harmful drinking behavior 196 (72.1) 204 (87.2)
 Not harmful drinking behavior 76 (27.9) 30 (12.8)
Cannabis use P > .1
 Yes 184 (67.6) 142 (60.7)
  GG 143 (77.7) 100 (70.4)
  T car 41 (22.3) 42 (29.6)
 Never 88 (32.4) 92 (39.3)
  GG 62 (70.4) 74 (80.4)
  T car 26 (29.6) 18 (19.6)
Frequency of use χ2 = 14.30, P < .001
Daily a 96 (63.6) 43 (39.8)
  GG 75 (78.1) 30 (69.8)
  T car 21 (21.9) 13 (30.2)
Weekly or less a 55 (36.4) 65 (60.2)
  GG 42 (76.4) 46 (70.8)
  T car 13 (23.6) 19 (29.2)
 No detailsa 33 34
Age of first use (M ± SD)a 16.18 ± 4.82 16.71 ± 2.91 P > .1
  GG (M ± SD)a 16.24 ± 5.02 16.69 ± 2.96
  T car (M ± SD)a 15.97 ± 4.13 16.76 ± 2.87
Note: FEP, first-episode psychosis.
aIn those who had ever used cannabis.
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The analysis showed an increasing probability of suf-
fering from a psychotic disorder in T carrying cannabis 
users depending on frequency of use (N = 439, likelihood 
ratio test =6.50; P = .039). Among both occasional and 
daily cannabis users, T carrying subjects showed increased 
odds of having psychotic disorder when compared with 
GG subjects, but only among daily cannabis users did the 
increased odds of psychosis shown by T carrying subjects 
reach significance (OR = 4.82; 95% CI: 1.39,16.71). On the 
contrary, among those who had never used cannabis, the 
presence of the T allele was associated with lower odds of 
suffering a psychotic disorder (OR = 0.36; 95% CI: 0.10, 
1.37) compared with GG genotype, even if  the OR failed 
to reach significance (figure 1b).
Healthy Subjects Study
Demographic Measures and Allelic Distribution of the 
DRD2 rs1076560 Genotype. Tables 2 and 3 describe 
demographic measures and allelic distribution of the 
rs1076560 genotype of the 2 samples for the evaluation of 
schizotypal traits and cognitive performance respectively. 
After genotype determination, both groups (GG, T car-
riers) displayed Hardy-Weinberg equilibrium (all P > .1). 
Furthermore, SCZt and WMp genotype groups did not 
differ for any demographic measure (sex, age, parental 
socioeconomical status, handedness and total IQ, all P 
> .1). Moreover, there were no significant differences in 
demographics between cannabis users and cannabis naïve 
subjects (all P > .1; tables 2 and 3).
Pattern of Substance Use. Patterns of tobacco use (nico-
tine dependence), alcohol use (HD behavior), and canna-
bis use (lifetime exposure, frequency of use) are described 
in tables 2 and 3. SCzt and WMp genotype groups did 
not differ in their pattern of substance use; in addition, 
cannabis users and cannabis naïve subjects did not differ 
in their pattern of tobacco or alcohol use, in either the 
SCZt or WMp samples (all P > .1; tables 2 and 3).
Schizotypal Traits. Factorial ANOVA on SPQ score data 
revealed: a main effect of DRD2 rs1076560, with T carriers 
having increased schizotypy compared with GG subjects 
(F1,169 = 5.47; P =  .020); a trend toward a main effect of 
cannabis use approaching significance, with cannabis users 
tending to have increased schizotypy compared to cannabis 
naïve subjects (F1,169 = 3.42; P = .066). More importantly, 
there was an interaction between genotype and canna-
bis use (F1,166 = 4.05; P = .046). Fisher’s post hoc analysis 
revealed that, while cannabis use did not significantly affect 
schizotypy in the context of GG genotype, T carrying can-
nabis users had increased schizotypy compared with T car-
rying cannabis naïve subjects (P = .025), GG cannabis users 
(P = .001), and GG cannabis naïve subjects (P = .005) (fig-
ure 2a). Further ANCOVA on schizotypy in 124 out of 170 
individuals using gender, age, nicotine dependence and HD 
behavior as covariates, indicated that these potentially con-
founding variables did not affect the results significantly.
Cognitive Performance. Factorial ANOVA on working 
memory accuracy data demonstrated: a trend towards 
a main effect of DRD2 rs1076560 approaching signifi-
cance, with T carriers tending to have reduced accuracy 
compared with GG subjects (F1,220 = 3.04; P = .083); and 
a significant interaction between genotype and cannabis 
use (F1,217  =  6.49; P  =  .012). Fisher’s post hoc analysis 
revealed that, while cannabis use did not significantly 
affect working memory performance in the context of GG 
genotype, T carrying cannabis users performed less accu-
rately than T carrying cannabis naïve subjects (P = .008), 
GG cannabis users (P =  .003), and GG cannabis naïve 
subjects (P = .003) (figure 2b). No significant main effect 
or interaction of genotype and cannabis use was found 
on working memory reaction time. Further ANCOVA on 
Fig. 1. (a) Interaction between DRD2 rs1076560 and lifetime cannabis use on psychosis risk. (b) Interaction between DRD2 rs1076560 
and lifetime frequency of cannabis use on psychosis risk.
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accuracy and reaction time in 158 out of 221 individuals 
using gender, age, nicotine dependence, and HD behavior 
as covariates indicated that these potentially confounding 
variables do not affect the results.
Discussion
The present results indicate that rs1076560 interacts with 
cannabis use in modulating the risk of having a psychotic 
disorder, as well as schizotypal traits and cognitive perfor-
mance in healthy subjects. These results provide another 
instance of interaction between cannabis exposure and 
genetic variation on risk of develop a psychotic disorder. 
Moreover, they shed new light on the potential for canna-
bis use to alter cognition and induce psychosis-like symp-
toms in healthy people of specific genetic backgrounds.
Studies on gene by cannabis use interaction (G × E) on 
psychosis risk and psychosis-related endophenotypes have 
mainly included genes involved in the regulation of dopa-
minergic system.7,53–56 Caspi et al53 reported that variation 
in COMT, which encodes the enzyme catechol-O-methyl-
transferase (COMT) that plays an important role in the 
degradation of dopamine in brain, modulated the risk of 
cannabis users developing psychosis; however, this report 
has not been consistently replicated.57–59 On the other hand 
both published reports examining AKT1, which encodes 
the serine/treonine kinase AKT1, an integral part of the 
dopamine receptor 2 (DRD2) signaling cascade in the 
striatum, reported an interaction with cannabis use on the 
risk of psychosis.46,54 Therefore, other genes that regulate 
signaling pathways and impact on dopamine transmission 
may be plausible candidates for such G × E interaction.
Our candidate for a mediating role in the association 
between cannabis use and psychosis risk as well as between 
cannabis use and psychosis-related endophenotypes was 
the DRD2 gene. D2 receptors are privileged targets of 
antipsychotic drugs, which antagonize their activity.32 
Previous reports have suggested association between psy-
chosis and relatively greater D2 density in striatum,33 and 
an aberrant D2 signaling has been associated with clini-
cal symptoms.34 Also DRD2 rs1076560 has been associ-
ated with putatively greater levels of striatal dopamine.40 
Importantly, a recent study from the Schizophrenia 
Working Group of the Psychiatric Genomics Consortium 
Table 2. Description of the Sample for the Schizotypal Traits Evaluation 
Sample  
n = 170 (82 Males)
DRD2 rs1076560 
GG Subjects  
n = 116 (57 Males)
DRD2 rs1076560 
T Carriers  
n = 54 (1 TT)  
(25 Males)
Cannabis-Naïve 
Subjects  
n = 103 (50 Males)
Cannabis Users 
n = 67 (32 Males)
Age (M ± SD) 28.36 (8.23) 28.41 (8.29) 28.26 (8.18) 28.63 (8.64) 27.94 (7.60)
Range 19–51 19–51 19–49 19–51 19–50
Distribution n (%) n (%) n (%) n (%) n (%)
 18–29 134 (78.8) 91 (78.5) 43 (79.6) 82 (79.6) 52 (77.6)
 30–39 24 (14.1) 16 (13.8) 8 (14.8) 14 (13.6) 10 (14.9)
 40–49 10 (5.9) 7 (6) 3 (5.6) 6 (5.8) 4 (6)
 50–59 2 (1.2) 2 (1.7) 0 1 (1) 1 (1.5)
 60–65 — — — — —
M (SD) M (SD) M (SD) M (SD) M (SD)
PSES 42.65 (16.97) 43.01 (16.94) 41.67 (17.21) 42.80 (17.40) 42.42 (16.40)
Handedness 0.84 (0.26) 0.84 (0.26) 0.83 (0.27) 0.84 (0.27) 0.83 (0.27)
IQ 107.52 (11.78) 107.74 (11.41) 107.09 (12.72) 107.50 (11.32) 107.55 (12.72)
n (%) n (%) n (%) n (%) n (%)
Tobacco use
 ND yes 52 (41.9) 34 (40.5) 18 (45) 27 (36.5) 25 (50)
 ND no 72 (58.1) 50 (59.5) 22 (55) 47 (63.5) 25 (50)
 No details 46 32 14 29 17
Alcohol use
 HD yes 57 (46) 38 (45.2) 19 (47.5) 33 (44.6) 24 (48)
 HD no 67 (54) 46 (54.8) 21 (52.5) 41 (55.4) 26 (52)
 No details 46 32 14 29 17
Cannabis use
 Yes 67 (39.4) 46 (39.7) 21 (38.9)
 Never 103 (60.6) 70 (60.3) 33 (61.1)
 Dailya 8 (11.9) 5 (10.9) 3 (14.3)
 Weekly or lessa 59 (88.1) 41 (89.1) 18 (85.7)
Note: HD, harmful drinking; IQ, Intelligence Quotient; ND, nicotine dependence; PSES, parental socioeconomical status.
aIn those who had ever used cannabis; there were no significant differences between GG subjects and T carrying subjects as well as 
between cannabis users and cannabis-naïve subjects among demographic measures and substance use (all P > .1).
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Fig. 2. Interaction between DRD2 rs1076560 and lifetime cannabis use on healthy subjects’ Schizotypy (SPQ questionnaire) and 
Working Memory Test (2-back) accuracy.
Table 3. Description of the Sample for the Cognitive Performance Evaluation
Sample  
n = 221  
(120 Males)
DRD2 rs1076560  
GG Subjects  
n =173 (93 Males)
DRD2 rs1076560 T 
Carriers  
n = 48 (3 TT)  
(27 Males)
Cannabis-Naïve 
Subjects  
n = 126 (67 Males)
Cannabis Users  
n = 95 (53 Males)
Age (M ± SD) 27.40 (7.69) 27.31 (7.70) 27.75 (7.71) 27.23 (7.46) 27.63 (8.02)
 Range 18–63 18–63 18–58 18–58 18–63
 Distribution n (%) n (%) n (%) n (%) n (%)
 18–29 173 (78.3) 137 (79.2) 36 (75) 99 (78.6) 74 (77.9)
 30–39 29 (13.1) 21 (12.1) 8 (16.7) 17 (13.5) 12 (12.6)
 40–49 14 (6.3) 11 (6.4) 3 (6.2) 7 (5.5) 7 (7.5)
 50–59 4 (1.8) 3 (1.7) 1 (2.1) 3 (2.4) 1 (1)
 60–65 1 (0.5) 1 (0.6) — — 1 (1)
M (SD) M (SD) M (SD) M (SD) M (SD)
PSES 43.13 (16.53) 43.45 (16.67) 41.99 (16.14) 44.54 (16.51) 41.26 (16.45)
Handedness 0.82 (0.31) 0.81 (0.32) 0.85 (0.29) 0.80 (0.36) 0.85 (0.29)
IQ 107.05 (11.71) 107.55 (11.96) 105.25 (10.71) 107.48 (11.74) 106.47 (11.72)
n (%) n (%) n (%) n (%) n (%)
Tobacco use
 ND yes 68 (43) 53 (42.4) 15 (45.5) 37 (42) 31 (44.3)
 ND no 90 (57) 72 (57.6) 18 (54.5) 51 (58) 39 (55.7)
 No details 63 48 15 38 25
Alcohol use
 HD yes 76 (48.1) 58 (46.4) 18 (54.5) 42 (47.7) 34 (48.6)
 HD no 82 (51.9) 67 (53.6) 15 (45.5) 46 (52.3) 36 (51.4)
 No details 63 48 15 38 25
Cannabis use
 Yes 95 (43) 77 (44.5) 18 (37.5)
 No 126 (57) 96 (55.5) 30 (62.5)
 Dailya 10 (10.5) 8 (10.4) 2 (11.1)
 Weekly or lessa 85 (89.5) 69 (89.6) 16 (88.9)
Note: HD, harmful drinking; IQ, Intelligence Quotient; ND, nicotine dependence; PSES, parental socioeconomical status.
aIn those who had ever used cannabis; there were no significant differences between GG subjects and T carrying subjects as well as 
between cannabis users and cannabis-naïve subjects among demographic measures and substance use (all P > .1).
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has indicated that DRD2, rs2514218, is also associ-
ated with diagnosis of schizophrenia,35 and this poly-
morphism is in linkage disequilibrium with rs1076560 
(r2 = 0.3, D’ = 0.54), albeit not strongly. In addition, the 
primary central effects of the psychostimulant drugs are 
enhancement of the dopamine concentration in the syn-
aptic cleft and activation of D2-like dopamine receptors 
in the nucleus accumbens.60–62
Given the evidence that dopaminergic signaling is 
altered in schizophrenia patients and cannabis users31,63 
and that DRD2 variation seems to be relevant for both 
psychotic symptoms and cognitive alteration,36,37,40,41 we 
investigated if  DRD2 variation concurs to the psychosis-
inducing effects of cannabis use. Our results indicate that 
the effect of lifetime cannabis use on the risk of suffering 
from a psychotic disorder as well as on the likelihood of 
presenting psychosis-like symptoms and altered cogni-
tion differ according to DRD2 rs1076560 genotype.
In the case-control study, we found an interaction between 
cannabis use and rs1076560 on psychosis risk, T carrying 
subjects showing an increased risk of having a psychotic dis-
order in the context of cannabis use compared to GG sub-
jects. Our results suggest that specific DRD2 variation could 
represent a genetic vulnerability to the cannabis-induced 
increased risk of psychosis. A previous study indicated that 
the risk of psychosis depends, in part, on how frequently 
people use cannabis.43 Consistent with that study, a second 
analysis showed that in the context of occasional canna-
bis use, T carrying cannabis users have a relatively small 
increase in their psychosis risk which failed to reach signifi-
cance. However, T carrying subjects who reported daily can-
nabis use showed the greatest risk of psychosis.
Our findings support previous reports suggesting that 
genetic variation within genes that regulate signaling 
pathways and impact on dopamine transmission influ-
ences the risk of developing a psychotic disorder in can-
nabis users depending on the frequency of use.46,54 Our 
results indicate a model of interaction known as “quali-
tative G × E interaction” with a cross over pattern: car-
riers of the DRD2 rs1076560 T allele, compared to GG 
subjects, have a lower probability of psychotic disorder 
if  they never used cannabis but a higher probability if  
they have a history of cannabis use, especially of daily 
use. Our findings are in line with previous results in the 
field,15,46,53 and indicate that specific minor alleles may 
prevent or promote the risk for psychosis depending on 
the presence of a history of cannabis use. Such findings 
require validation in experimental designs and animal 
studies where both changes in the exposure and in the 
genotype can be modelled.
In the healthy subjects study, cannabis users had higher 
schizotypal symptoms than cannabis naïve subjects, in 
line with previous reports on a relation between canna-
bis use and greater schizotypy.9 In addition, we found 
an interaction between cannabis use and rs1076560 on 
schizotypy. In particular, in the context of cannabis use, 
carriers of the rs1076560 T allele had greater schizotypal 
symptoms compared to the other groups while cannabis 
use did not significantly increase schizotypal symptoms in 
the context of GG genotype. This result extends previous 
findings64 and suggests a moderating effect of variation 
in DRD2 on the relationship between cannabis use and 
schizotypy. Moreover, as elevated schizotypy and canna-
bis use have been associated with increased risk for psy-
chosis,8,65 our result implicates the T allele of rs1076560 
in genetic vulnerability to cannabis-induced increased 
psychosis-proneness in healthy subjects.
Finally, we find an interaction between cannabis use 
and rs1076560 on cognitive performance. Consistently 
with other results from this study, carriers of  the 
rs1076560 T allele performed less accurately on a work-
ing memory task compared to other groups. Again, can-
nabis use did not significantly affect working memory 
performance in the context of  GG genotype. This find-
ing extends previous reports on association between 
cannabis use and cognitive processing in healthy sub-
jects,12–15 suggesting that discrepancies in these stud-
ies may also be because of  genetic variation having an 
impact on cognitive phenotypes.66 This result is also 
consistent with previous findings indicating that T car-
rying subjects show less efficient prefronto-striatal activ-
ity and reduced performance during working memory.37 
Our result, together with this latter report, suggest that 
rs1076560 T allele, which per se seems to be related to 
less efficient cognitive performance,37,41 may represent 
a genetic vulnerability to cannabis-induced deleterious 
effects on cognition.
The lack of a T allele “protective” effect in cannabis-
naïve healthy subjects’ schizotypy levels and cognitive per-
formance could be due to several factors. Even if an allele 
conferred protection against a disease, it is not obvious that 
it would give advantage in terms of cognitive performance 
or in reducing schizotypal traits among healthy individu-
als. Several studies indicate that brain-imaging techniques 
have the potential to address a number of cognitive psy-
chology questions with a higher degree of inferential and 
statistical power than the more traditional measures of 
cognitive psychology.67 Thus, a previous study reported 
that behavioral analyses alone were not able to detect a 
“protective” effect of CNR1 genetic variation on working 
memory performance in cannabis-naïve healthy subjects 
(ie better performance), while related imaging analyses 
revealed a more efficient prefrontal connectivity.15 Finally, 
the fact that the T allele in the absence of cannabis use is 
protective in the context of a disease does not necessar-
ily translate to a population of healthy subjects in whom 
schizotypy does not translate into a full blown disease, 
probably because their genetics are more protective by 
definition. Also, the interaction between frequency of can-
nabis use and rs1076560 on risk of psychosis fails to reach 
significance for the T allele “protective” effect in cannabis-
naïve subjects, possibly due to reduced statistical power.
1180
M. Colizzi et al
The rs1076560 T allele has been previously associ-
ated with putatively greater levels of  striatal dopamine,40 
thus providing a possible neurobiological mechanism for 
the results of  this study. More specifically, our results 
together with this previous report suggest that genetically 
determined increased dopamine levels in the striatum40 
may modulate the psychosis-inducing effect of  canna-
bis use. This interpretation is consistent with the classi-
cal hypothesis of  a high release of  striatal dopamine in 
schizophrenia32 and with the evidence that drugs increas-
ing dopamine release can induce or worsen psychosis.27 
In other words, as Δ9-THC can alter dopaminergic sig-
naling,28–31 the interaction between DRD2 rs1076560 and 
cannabis use elicits the T allele related genetic vulnerabil-
ity, due to an alteration in striatal dopamine. However, 
these findings need to be replicated. Even if  gene by 
environment (G × E) research has received widespread 
attention, G × E findings remain controversial, suggest-
ing that direct replications deserve more attention that 
novel findings or indirect replications.68 Moreover, longi-
tudinal studies are needed to express conclusively on the 
direction of  the association between DRD2 rs1076560 
and cannabis-related psychosis. Even if  our findings 
together with the previous literature43 suggest that can-
nabis users could develop psychosis based on a specific 
genetic background, results do not exclude the possibil-
ity that some patients use cannabis to ameliorate certain 
internal feelings or symptoms of  psychosis. Cannabis 
use as self-medication for psychosis could coexist with 
cannabis-induced psychosis via genetics. Further studies 
are also needed to assess possible differences in canna-
bis-related psychosis risk among T carrying individuals 
due to ethnicity. Even if  our analyses revealed that eth-
nicity is not likely to strongly affect the results of  this 
study, the data are too limited to come to strong con-
clusions concerning ethnicity. Finally, the presence of 
only a limited number of  subjects with daily cannabis 
use in the healthy subjects’ study is a limitation which 
needs to be taken into account. We could not test for 
an interaction between frequency of  cannabis use and 
DRD2 genotype on healthy subjects’ levels of  schizotypy 
and working memory performance because of  the very 
limited statistical power.
These results support the theory that some individuals 
carry genetic vulnerability to the psychotogenic effect of 
cannabis. The character of this vulnerability is likely to 
be a polygenic gene-environment interaction. Identifying 
those genes and organizing them into genetic pathways 
will facilitate understanding the mechanisms that mod-
ulate the relationship between cannabis exposure and 
psychosis.
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